血管内皮生长因子与非酒精性脂肪性肝病

李娟; 张岭漪

血管内皮生长因子与非酒精性脂肪性肝病

李娟,
张岭漪

兰州大学第二医院肝病科甘肃省消化肿瘤重点实验室

基金项目:

甘肃省科学事业费科技项目(QS012-C33-41)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2325
- HTML全文浏览量: 24
- PDF下载量: 885
- 被引次数: 0
出版历程
- 出版日期: 2011-08-20

Vascular endothelial growth factor and nonalcoholic fatty liver disease

Research funding:

摘要

摘要: 非酒精性脂肪性肝病(NAFLD)是影响公共健康的全球性疾病,其病理变化可向非酒精性单纯性脂肪肝(NAFL)、脂肪性肝炎(NASH)甚至脂肪性肝硬化(FLC)发展。虽然NAFLD的这些病理进展机制尚未明确,但仍有一些实验研究提示了可能的诱发机制。其中血管内皮生长因子(VEGF)在促进NAFLD肝脏炎症、肝纤维化中发挥着重要的作用。本文就VEGF与NAFLD关系的研究进展予以综述。
- 血管内皮生长因子类 /
- 脂肪肝
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a prevalent public health problem worldwide, whose pathologic changes are considered to cover a spectrum of disease activity including nonalcoholic fatty liver (NAFL) , nonalcoholic steatohepatitis (NASH) and even fatty liver cirrhosis (FLC) .Although the mechanism from NAFL to FLC has still been unclear, some researches showed the possible inducement mechanism, among which vascular endothelial growth factor (VEGF) playing a key role in promoting the liver inflammation and fibrosis of NAFLD.This article will review the recent findings concerning the relationship between VEGF and NAFLD.
- vascular endothelial growth factors /
- fatty liver

HTML全文

参考文献(20)

[1]Saranadasa M, Wang ES.Vascular endothelial growth factor inhibi-tion:Conflicting roles in tumor growth[J].Cytokine, 2011, 53 (2) :115-129.

[2]Farrell GC, Larter CZ.Nonalcoholic fatty liver disease:From steato-sis to cirrhosis[J].Hepatoogy, 2006, 43 (S1) :S99-S112.

[3]Kitade M, Yoshiji H, Kojima H, et al.Leptin-mediated neovas-cularization is a prerequisite for progression of nonalcoholic steato-hepatitis in rats[J].Hepatology, 2006, 44 (4) :983-991.

[4]Carpenter B, Lin Y, Stoll S, et al.VEGF is crucial for the hepaticvascular development required for lipoprotein uptake[J].Develop-ment, 2005, 132 (14) :3293-3303.

[5] LeCouter J, Moritz DR, Li B, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1[J]. Science, 2003, 299 (5608) : 890-893.

[6]Huanq XD, Fan Y, Zhang H, et al.Serum leptin and soluble lep-tin receptor in non-alcoholic fatty liver disease[J].World J Gas-troenterol, 2008, 14 (18) :2888-93.

[7]Minicis AD, Seki E, Oesterreicher C, et al.Reduced nicotinamideadenine dinucleotide phosp-hate oxidase mediates fibrotic and in-flammatory effects of leptin on hepatic stellate cells[J].Hepatolo-gy, 2008, 48 (6) :2016-2026.

[8]Aleffi S, Petral I, Bertolani C, et al.Upregulation of proinflamma-tory and proangiogenic cytokines by leptin in human hepatic stellatecells[J].Hepatology, 2005, 42 (6) :1339-1348.

[9]Rosmorduc O, Housset C.Hypoxia:a link between fibrogenesis, angiogenesis, and carcinge-nesis in liver disease[J].Semin Liv-er Dis, 2010, 30 (3) :258-270.

[10]Matsumoto K, Imagawa S, Obara N, et al.2-oxoglutarate down-regulates expression of vasc-ular endothelial growth factor anderythropoietin through decreasing hypoxia-inducible factor-1αand inhibits angiogenesis[J].J Cell Physiol, 2006, 209 (2) :333-340.

[11]Wang B, Wood IS, Trayhurn P.Hypoxia induces leptin gene ex-pression and secretion in human preadipocytes:differentialeffects of hypoxia on adipokine expression by preadipo-cytes[J].J Endocrinol, 2008, 198 (1) :127-134.

[12] Wang SN, Chuang SC, Yeh YT, et al. Potential prognostic value of leptin receptor in hepato- cellular carcinoma[J]. Clin Pathol, 2006, 59 (12) : 1267-1271.

[13]Kaji K, Yoshiji H, Kitade M, et al.Impact of insulin resist-ance on the progression of chronic liver disease[J].Int JMol Med, 2008, 22 (60) :801-808.

[14]Gomez-Ambrosi J, Catalan V, Rodriguez A, et al.Invove-ment of serum vascular endothelial growth factor familymembers in the development of obesity in mice and humans[J].J Nutr Biochem, 2009, 21 (8) :774-780.

[15] Prieto-Hontoria PL, Perez-Matute P, Fernandez- Galilea M, et al. Role of obesity- asssociated dysfunctional adipose tissue in cancer: A molecular nutrition approach[J]. Biochim Biophys Acta, 2010, 1807 (6) : 664-678.

[16] Varela-Rey M, Embade N, Ariz U, et al. Non-alcoholic steatohepatitis and animal models: understanding the human disease[J]. Int J Biochem Cell B, 2009, 41 (5) : 969-976.

[17]Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ.Adipo-kines in nonalcoholic steatoheaptitis:from pathogenesis to im-plications in disgnosis and therapy[M].Hindawi Publishing Cor-poration:Mediators of Inflammation, 2009:1-8.

[18]Horiguchi N, Takayama H, Toyoda M, et al.Hepatocyte growthfactor promotes hepatocarci-nogenesis through c-Mel auto-crine activation and enhanced angiogenesis in transgenic micetreated with diethylnitrosamine[J].Oncogene, 2002, 21 (12) :1791-1799.

[19]Farrell GC, Chitturi S, Lau GK, et al.Guidelines for the as-sessment and management of non-alcoholic fatty liver dis-ease in the Asia-Pacific region:executive summary[J].JGastroen Hepatol, 2007, 22 (6) :775-777.

[20]Starley BQ, Calcagno CJ, Harrison SA.Nonalcoholic Fatty LiverDisease and Hepatocellular Carcinoma:A Weighty Connection[J].Hepatology, 2010, 51 (5) :1820-1832.

施引文献

资源附件(0)

访问统计